Armoring CAR-Ts to produce interleukin-15 (IL15) or interleukin-12 (IL12) has been shown to drive CAR-T expansion and resistance to immunosuppression, respectively, enhancing anti-tumor activity. This evidence concerns the gene IL15 and neoplasm.